Tech Transfer Central
Tech Transfer eNews

Tech Transfer E-News provides a weekly round-up of current news and information in the world of tech transfer, delivered every Wednesday (sign up here). It is published by Technology Transfer Tactics newsletter, which is available as a monthly subscription. For more information or to order a subscription click here, or for a sample issue, click here.

U of St. Andrews start-up develops promising COVID-19 therapeutics

A spinout from the University of St. Andrews in Scotland has completed studies on new treatments for COVID-19, and the results look promising.

Pneumagen Ltd. has developed first-in-class multivalent Carbohydrate-Binding Molecules (mCBMs) to prevent and treat the novel coronavirus. In three recent studies, the mCBMs were shown to decrease the presence of SARS-CoV-2, the virus that causes COVID-19. The start-up plans to launch clinical testing of its therapeutics, including its proprietary drug Neumifil.

Before the coronavirus pandemic, Pneumagen was developing Neumifil and other mCMBs for the universal treatment of coronavirus infections, such as influenza and the common cold. According to CEO Douglas Thomson, the start-up’s current work on COVID-19 drugs builds on those previous efforts.

“Today’s positive results from in vitro studies of our mCBMs against coronaviruses show that glycan-binding has the potential to prevent and treat the infection,” says Thomson. “This further supports the value of our universal therapeutic modality to block access to lung cells of SARS-CoV-2, as well as other viruses, that cause respiratory tract infections, providing the potential for a pan-viral respiratory product. Our goal is now to rapidly begin clinical testing for the prevention and treatment of COVID-19.”  Source:

Posted under: Tech Transfer e-News